AMD Biomarkers Identified by Metabolomics
The next ’omic.
Brolucizumab Shows Continued Efficacy at Year 2
Additional data presented from phase 3 trials.
Faricimab 16-Week Efficacy at 1 Year Confirmed
A 6-mg dose shows no new safety concerns.
Ocular Melanoma Therapy Promising at 1 Year
Aura Biosciences cites stable disease in trial.
Positive 1-Year Results for Eylea in Nonproliferative Diabetic Retinopathy
New data will support approval application.
Suprachoroidal Therapy Fails in Retinal Vein Occlusion Study
The phase 3 SAPPHIRE trial did not meet its primary endpoint.
Update on Nanotechnology in Retina
Developments will alter the treatment paradigm of retinal conditions.
Patient Selection for the Implantable Miniature Telescope
Treatment goes beyond surgery.
Home Monitoring Applications for Retinal Disease
New developments provide more options to patients.
Multiple-Sclerosis–Associated Uveitis
Considerations for treatment of this unique patient population.
Treatment of Pigment Epithelial Detachments in Age-Related Macular Degeneration
A significant cause of visual morbidity in neovascular AMD, PEDs remain a treatment challenge.
CODING Q&A: Coding for Optical Coherence Tomography Angiography
Confusion persists around what constitutes angiography.
RETINA CONVERSATIONS: Leading Adverum at the Frontier of Gene Therapy
A conversation with Leone Patterson, BS, MBA.
NEW PRODUCT APPLICATIONS: Mobile App Enables Patients to Self-Monitor Vision Changes
Alleye can detect disease early and track disease progression.
Xipere Resolves Haze in Uveitic Macular Edema
Positive results in a key measure for uveitis.